Ipamorelin and Trazodone Interaction: What Patients and Prescribers Need to Know

Direct answer

Ipamorelin, a compounded growth hormone-releasing peptide with no FDA approval, and trazodone, an FDA-approved SARI antidepressant used off-label for insomnia, have no documented pharmacokinetic interaction because ipamorelin is not metabolized through the CYP450 system that clears trazodone. The realistic concern is pharmacodynamic: both drugs can independently cause drowsiness, and using them close together may produce more sedation than either alone. No published human trial has tested ipamorelin plus trazodone directly, so this assessment rests on the separate, better-documented pharmacology of each drug rather than on combination-specific evidence, and anyone using both should discuss timing and monitoring with the prescriber managing the trazodone.

What each drug is

Ipamorelin acetate is a synthetic pentapeptide that acts on the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus to stimulate a pulse of growth hormone release. It has no FDA-approved indication in the United States. When it appears in clinical use, it is typically dispensed by a compounding pharmacy for off-label purposes, which means its manufacturing, purity, and dosing are not standardized the way an FDA-approved drug's are. Human interaction and safety data are limited compared with approved medications.

Trazodone hydrochloride is a serotonin antagonist and reuptake inhibitor (SARI) that the FDA approved for major depressive disorder. Its sedating profile, driven mainly by histamine H1 and alpha-1 adrenergic receptor blockade, has made it a frequently used off-label sleep aid, though that use is not the approved indication on its label. The FDA-approved label lists a dose range for depression of 150 to 600 mg per day; off-label insomnia doses used in practice are typically much lower, but any specific dose should come from the prescribing clinician rather than this article, per FDA-approved trazodone labeling.

Why this pairing raises a sedation question, not a metabolic one

Ipamorelin is a peptide. Peptides are broken down by proteases in blood and tissue, not by liver CYP450 enzymes, and this general property of peptide drugs is well established in the peptide pharmacology literature. Trazodone, by contrast, is extensively metabolized by CYP3A4 into an active metabolite. Because ipamorelin has no known effect on CYP3A4 activity, there is no established mechanism by which it would raise or lower trazodone blood levels, and no mechanism by which trazodone's CYP3A4 metabolism would change ipamorelin's clearance.

That leaves a pharmacodynamic question instead. Ipamorelin's GHS-R1a activity in the brain has been associated with mild, transient drowsiness in some users, and growth hormone secretagogues as a class have been linked to changes in sleep architecture in the sleep-endocrinology literature. Trazodone's sedative effect through H1 and alpha-1 blockade is well documented in its own labeling and in sleep-medicine research. Two independently sedating mechanisms acting at the same time can plausibly add up to more drowsiness than either produces alone. This is a reasonable pharmacological inference, not a finding confirmed by a trial of the combination itself.

Standard drug interaction checkers (Lexicomp, Micromedex, and similar tools) are built primarily to flag CYP and P-glycoprotein interactions. Because ipamorelin does not act through those pathways, these tools are likely to return "no interaction found" for this pair. That result reflects the limits of what those databases screen for, not a confirmed absence of any interaction risk, and clinicians should not treat a clean database check as reassurance about additive sedation.

What trazodone's serotonergic activity might mean for the growth hormone axis

Serotonin signaling is known to stimulate hypothalamic growth-hormone-releasing hormone (GHRH) neurons, and there is older literature reporting acute GH responses to serotonergic agents in healthy volunteers. If that mechanism applies to trazodone specifically, it raises a plausible question of whether trazodone could nudge ipamorelin's GH pulse slightly higher on nights when both are used. This has not been studied directly, and no source in this review confirms trazodone's own acute GH effect in the specific dose ranges used for insomnia. It should be treated as a hypothesis worth mentioning to a prescriber, not as an established pharmacologic fact. There is also no evidence that any acute effect, if real, would translate into a sustained rise in IGF-1, which is the marker typically used to monitor a growth-hormone-secretagogue protocol over time.

Evidence-status assessment: ipamorelin plus trazodone

Anything in the "not established" or "requires verification" rows should be raised explicitly with the prescriber and pharmacist rather than assumed.

Special populations

Older adults. Trazodone is flagged in the American Geriatrics Society's Beers Criteria as a medication to use cautiously in older adults because of sedation and orthostatic hypotension risk. Adding a second drug with its own sedation profile increases the importance of a fall-prevention conversation and closer initial follow-up in this age group. This caution applies to trazodone on its own; it has not been separately validated for the ipamorelin-trazodone combination.

Obstructive sleep apnea. Growth hormone and growth hormone secretagogues are treated with caution in patients with untreated obstructive sleep apnea in Endocrine Society guidance on GH-axis therapy, and sedating medications can also affect respiratory drive and sleep architecture. Anyone with untreated or poorly controlled sleep apnea should raise this specifically before starting ipamorelin while already on trazodone.

Pregnancy and lactation. Ipamorelin has no FDA approval and no established human pregnancy safety data. Trazodone carries legacy Category C labeling. Neither drug's safety in combination during pregnancy or lactation has been studied, and the combination should not be used in this population without a documented, individualized clinical justification from the treating physician.

Other CNS-active medications. Anyone taking an opioid, benzodiazepine, muscle relaxant, or gabapentinoid alongside trazodone should have a full CNS-depressant review before adding ipamorelin. Regulatory warnings about combining opioids with benzodiazepines illustrate the broader principle that stacking CNS depressants raises risk in ways that individual two-drug interaction checks can miss.

What to discuss with a prescriber or pharmacist before combining these

• Confirm the trazodone dose and what time of day it is taken.
• Ask whether ipamorelin injection timing should be separated from the trazodone dose, and by how much, based on the specific regimen.
• Ask what baseline labs make sense before starting, and how often IGF-1 and other markers should be rechecked given both drugs.
• Report any morning grogginess that persists well past waking, dizziness on standing, or falls, since these suggest the combination needs adjustment rather than automatic discontinuation of one drug.
• Avoid adding alcohol, benzodiazepines, or sedating antihistamines on top of this combination without medical guidance.
• Do not drive or operate machinery until you know how the combination affects you; FDA-approved trazodone labeling warns that patients should be cautioned about hazardous machinery, including driving, until they are certain the medication does not impair them.
• If sleep apnea, pregnancy, or another CNS-active medication is part of the picture, raise it before starting, not after.

This list is meant to prepare a conversation with a licensed prescriber. It is not a substitute for that conversation and does not set an individual dose or schedule.

Evidence boundary

Established: Trazodone's mechanism, its CYP3A4 metabolism, its FDA-approved indication, and its labeled sedation and driving warnings come from its FDA label. Ipamorelin's mechanism of action on GHS-R1a and its lack of hepatic CYP metabolism reflect general, widely accepted peptide and GHRP pharmacology.

Plausible but unproven: That combining ipamorelin and trazodone produces additive sedation beyond either drug alone; that trazodone's serotonergic activity could modestly influence ipamorelin's GH pulse in people using both; that a fixed timing gap between doses meaningfully reduces overlap risk in practice.

Not established: Any specific magnitude of added sedation risk; any confirmed effect of trazodone on IGF-1 levels in people using ipamorelin; a formal FDA or guideline-based severity rating for this exact combination, since neither agency nor major guideline body has evaluated ipamorelin as an approved product.

No randomized trial or observational study of ipamorelin plus trazodone in humans was identified for this review. Readers and clinicians should treat this article as a pharmacology-based risk assessment, not as a substitute for a primary-literature search or a pharmacist-led interaction check specific to an individual's full medication list.